Jonathan Aschoff
Stock Analyst at Roth Capital
(0.49)
# 4,142
Out of 5,182 analysts
39
Total ratings
24.49%
Success rate
-34.76%
Average return
Main Sectors:
Stocks Rated by Jonathan Aschoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTHS Pelthos Therapeutics | Maintains: Buy | $57 → $55 | $25.45 | +116.11% | 2 | Feb 26, 2026 | |
| GTBP GT Biopharma | Initiates: Buy | $11 | $0.38 | +2,793.98% | 1 | Dec 2, 2024 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $19 → $21 | $10.61 | +97.93% | 2 | Sep 24, 2024 | |
| APVO Aptevo Therapeutics | Maintains: Buy | $199,800 → $106,560 | $5.35 | +1,991,675.70% | 3 | Sep 23, 2024 | |
| BRTX BioRestorative Therapies | Maintains: Buy | $15 → $18 | $0.25 | +6,986.61% | 4 | Aug 14, 2024 | |
| NUWE Nuwellis | Reiterates: Buy | $714 | $1.11 | +64,224.32% | 2 | Aug 13, 2024 | |
| GOVX GeoVax Labs | Initiates: Buy | $500 | $1.42 | +35,111.27% | 1 | Jul 16, 2024 | |
| MBRX Moleculin Biotech | Maintains: Buy | $1,000 | $2.49 | +40,060.64% | 2 | Apr 12, 2024 | |
| CLRB Cellectar Biosciences | Maintains: Buy | $600 → $840 | $3.18 | +26,315.09% | 4 | Mar 28, 2024 | |
| HSDT Solana Company | Maintains: Buy | $3,750 → $18,000 | $2.16 | +833,233.33% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $12.49 | +140.19% | 3 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $200 | $6.58 | +2,939.51% | 1 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $9.56 | +46.44% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28,800 → $86,400 | $1.07 | +8,074,666.36% | 2 | Feb 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $8 | $1.49 | +436.91% | 1 | Jun 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $2.23 | +4,384.30% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $1.15 | +34,682.61% | 1 | Nov 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $38 | $8.13 | +367.40% | 1 | Mar 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $96 | $1.14 | +8,321.05% | 3 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $1.54 | +744.16% | 1 | Dec 19, 2019 |
Pelthos Therapeutics
Feb 26, 2026
Maintains: Buy
Price Target: $57 → $55
Current: $25.45
Upside: +116.11%
GT Biopharma
Dec 2, 2024
Initiates: Buy
Price Target: $11
Current: $0.38
Upside: +2,793.98%
Zevra Therapeutics
Sep 24, 2024
Maintains: Buy
Price Target: $19 → $21
Current: $10.61
Upside: +97.93%
Aptevo Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $199,800 → $106,560
Current: $5.35
Upside: +1,991,675.70%
BioRestorative Therapies
Aug 14, 2024
Maintains: Buy
Price Target: $15 → $18
Current: $0.25
Upside: +6,986.61%
Nuwellis
Aug 13, 2024
Reiterates: Buy
Price Target: $714
Current: $1.11
Upside: +64,224.32%
GeoVax Labs
Jul 16, 2024
Initiates: Buy
Price Target: $500
Current: $1.42
Upside: +35,111.27%
Moleculin Biotech
Apr 12, 2024
Maintains: Buy
Price Target: $1,000
Current: $2.49
Upside: +40,060.64%
Cellectar Biosciences
Mar 28, 2024
Maintains: Buy
Price Target: $600 → $840
Current: $3.18
Upside: +26,315.09%
Solana Company
Mar 5, 2024
Maintains: Buy
Price Target: $3,750 → $18,000
Current: $2.16
Upside: +833,233.33%
Feb 20, 2024
Reiterates: Buy
Price Target: $30
Current: $12.49
Upside: +140.19%
Aug 29, 2023
Reiterates: Buy
Price Target: $200
Current: $6.58
Upside: +2,939.51%
Aug 14, 2023
Reiterates: Buy
Price Target: $14
Current: $9.56
Upside: +46.44%
Feb 14, 2023
Maintains: Buy
Price Target: $28,800 → $86,400
Current: $1.07
Upside: +8,074,666.36%
Jun 15, 2022
Reinstates: Buy
Price Target: $8
Current: $1.49
Upside: +436.91%
Feb 25, 2022
Initiates: Buy
Price Target: $100
Current: $2.23
Upside: +4,384.30%
Nov 24, 2021
Initiates: Buy
Price Target: $400
Current: $1.15
Upside: +34,682.61%
Mar 11, 2021
Initiates: Buy
Price Target: $38
Current: $8.13
Upside: +367.40%
Nov 17, 2020
Downgrades: Sell
Price Target: $96
Current: $1.14
Upside: +8,321.05%
Dec 19, 2019
Initiates: Buy
Price Target: $13
Current: $1.54
Upside: +744.16%